Vijay Peddareddigari

Author

Also Known As

V. G. Peddareddigari, V. Peddareddigari, Vijay G R Peddareddigari, Vijay G. Peddareddigari, Vijay G. R. Peddareddigari, Vijay G.R. Peddareddigari, Vijay GR Peddareddigari, Vijay Peddareddigari

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Autolus (United Kingdom)University College London University College London Hospitals NHS Foundation Trust Sarah Cannon The University of Texas MD Anderson Cancer Center

About

Vijay Peddareddigari is an author at Autolus (United Kingdom) specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.7K
2	Pathology	7	7	442
3	Cell Biology	4	4	225
4	Health Sciences	1	1	51
5	Immunology	1	1	20

Vijay Peddareddigari

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, The Lancet Oncology Pharmacological StudyEfficacy DataPharmacologyClinical TrialsPharmacotherapy	2012	554
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, The Lancet Oncology MedicineMelanomaPharmacologyImmune Checkpoint InhibitorPharmacotherapy	2012	534
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, Journal of Clinical Oncology	2015	371
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Nature Medicine	2021	260
The Tumor Microenvironment in Colorectal Carcinogenesis Vijay Peddareddigari, Dingzhi Wang, Raymond N. DuBois Cancer Microenvironment Biological MicroenvironmentsColorectal CancerPathologyColorectal CarcinogenesisMedicine	2010	250
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors Jean‐Charles Soria, Hui Gan, Sarah P. Blagden, Annals of Oncology Pharmacodynamic StudyMedicineCell AdhesionReceptor Tyrosine KinasePharmacology	2016	140
<i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer Kartik Konduri, Jean‐Nicolas Gallant, Young Kwang Chae, Cancer Discovery	2016	124
Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma Claire Roddie, Lazaros J. Lekakis, Maria A. V. Marzolini, Blood	2023	68
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients Andrew D.J. Pearson, Claudia Rössig, Giovanni Lesa, European Journal of Cancer	2020	66
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer David R. Gandara, Natasha B. Leighl, Jean‐Pierre Delord, Journal of Thoracic Oncology Phase 1/1BMedicineCancer ManagementPharmacologyClinical Trials	2016	51

Page 1